Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSCII-guided Low-dose ART in HIV
NCT02632474Phase 4Completed
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate, lamivudine and efavirenz in human immunodeficiency virus infection (HIV). Primary endpoint: HIV viral load at 48 weeks. Started Apr 2015; status: completed.
02
Drugs
tenofovir disoproxil fumaratelamivudineefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02632474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632474.